PEG-MGF

PEG-MGF is a pegylated mechano growth factor peptide derived from insulin-like growth factor-1 that extends the half-life of native MGF from minutes to days and is used therapeutically to stimulate muscle repair, regeneration, and recovery following injury or in conditions involving muscle wasting.

Brief glance

The primary outcome is Recovery & Repair, but it's also used for Performance, Anti-Aging. This compound is considered a Peptide. It may be compounded in 503A pharmacies where allowed. It is not listed under a DEA schedule.

Overview

PEG-MGF, or pegylated mechano growth factor, is a modified isoform of insulin-like growth factor-1 (IGF-1) designed as a pharmaceutical active ingredient to extend the short half-life of native MGF from minutes to 48-72 hours via polyethylene glycol conjugation. It functions as an anabolic peptide that promotes muscle stem cell proliferation, myoblast differentiation, and tissue repair in muscle, bone, tendon, and neural tissues following stress or injury. Common therapeutic roles include accelerating muscle recovery, reducing inflammation, and supporting regeneration, with bulk powder forms approved for pharmaceutical processing.

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic peptide derived from insulin-like growth factor-1 (IGF-1) that functions as an anabolic agent for muscle and soft tissue repair. The compound is a modified form of mechano growth factor, a naturally occurring peptide produced in response to mechanical stress or muscle damage, with polyethylene glycol conjugation added to extend its half-life from 5–7 minutes to approximately 48–72 hours. Pharmacologically, PEG-MGF operates by binding to muscle cell receptors to stimulate satellite cell proliferation and differentiation, promoting myoblast fusion, protein synthesis enhancement, and inhibition of protein breakdown. Primary therapeutic indications include treatment of muscle wasting disorders such as sarcopenia, bone and soft tissue repair following injury (tendons, ligaments, muscle), and recovery support in conditions including stroke and cardiac events. The pegylation modification protects the peptide from rapid degradation, enabling sustained biological activity and less frequent dosing intervals compared to unmodified MGF.

Benefits

PEG-MGF promotes muscle repair and regeneration by stimulating satellite cell activation, proliferation, and differentiation of muscle cells, supporting recovery from injury, sarcopenia, and eccentric muscle loading.¹,²,³ It enhances anabolic signaling for soft tissue repair including tendons, ligaments, and bones, while providing cardioprotective effects through inhibition of myocardial apoptosis and improved hemodynamic function post-infarction in animal models.¹,²,³,⁴ Additional preclinical evidence indicates benefits in wound healing, neuroprotection against neuronal degeneration, and osteogenic differentiation for bone and connective tissue strength.¹,⁴,⁵

Side effects

Common side effects of PEG-MGF include local injection site reactions such as pain, numbness, redness, swelling, and irritation, along with joint pain, muscle pain, stiffness, temporary water retention or swelling of extremities, fatigue, nausea, dry mouth, and potential hypoglycemia or drop in blood pressure.¹,⁶,⁷ Safety considerations encompass contraindication in patients with evidence of neoplastic activity, active intracranial lesions, or ongoing antitumor therapy, with discontinuation required if tumor growth occurs.⁶ Use caution in individuals prone to hypoglycemia, those with liver or kidney impairments, or pre-existing musculoskeletal conditions due to risks of abnormal tissue growth, inflammation, overactivation of muscle satellite cells, or PEG accumulation.¹,⁶,⁷,⁸ Pregnancy category B applies, with no adequate studies in pregnant women or nursing mothers, recommending use only if clearly needed.⁶ Additional precautions involve patient-specific dosing to prevent unwanted tissue hypertrophy, monitoring for rare allergic reactions like rash, and awareness of limited long-term clinical data, as PEG-MGF remains research-only in many regulatory contexts.⁶,⁷,⁸

Mechanisms of action

PEG-MGF, a pegylated form of mechano growth factor derived from the IGF-1 gene, binds to specific receptors on muscle cells, activating signaling cascades that stimulate satellite cell proliferation and differentiation for muscle repair.³,⁴,⁷ This process enhances protein synthesis, inhibits protein breakdown, and promotes myoblast fusion and hypertrophy in response to mechanical stress or damage.³,⁷ PEGylation with polyethylene glycol extends its short half-life from minutes to days, allowing prolonged local action and protection from rapid enzymatic degradation.¹,³,⁷ These effects support tissue regeneration, including upregulation of pathways like protein kinase C and Nrf2 for neuroprotection and anti-apoptotic activity in preclinical models.³,⁹